Search
Search
About
Log in
Join
Experiences with
Enzalutamide
Posts
Communities
833 public posts
Filter results
Research Study with Niaparib in combination with Abiraterone Acetate and Prednisone
The VA offered this or just
enzalutamide
. Any thoughts
The VA offered this or just
enzalutamide
. Any thoughts
DER326
in
Advanced Prostate Cancer
4 years ago
Adverse Events Related to Abiraterone and Enzalutamide Treatment
Clinicians should consider these data when treating cancer patients with abiraterone and
enzalutamide
.
Clinicians should consider these data when treating cancer patients with abiraterone and
enzalutamide
.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Rucaparib in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alteration
All patients had metastatic CRPC and had been previously treated with both a taxane-containing regimen and a novel hormone such as abiraterone or
enzalutamide
. All patients had progressive disease at the time of trial entry and all patients had a pathogenic alteration in BRCA1 or BRCA2.
All patients had metastatic CRPC and had been previously treated with both a taxane-containing regimen and a novel hormone such as abiraterone or
enzalutamide
. All patients had progressive disease at the time of trial entry and all patients had a pathogenic alteration in BRCA1 or BRCA2.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
[EAU-2020] Enzyme inhibition for overcoming CRPC.
In a second experiment performed in the same mouse model, animals were treated with vehicle,
enzalutamide
, 1 of the STS inhibitors, or
enzalutamide
plus the STS inhibitor.
In a second experiment performed in the same mouse model, animals were treated with vehicle,
enzalutamide
, 1 of the STS inhibitors, or
enzalutamide
plus the STS inhibitor.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Adding carboplatin to chemotherapy for mCRPC in post-second generation hormone therapy setting: Impact on response and survival
New study below. [1] "We retrospectively identified 150 mCRPC patients with disease progression on
enzalutamide
or abiraterone. Of these 150 patients, 92 patients were chemo-naïve while 58 patients had previously received docetaxel chemotherapy before being started on second HT.
New study below. [1] "We retrospectively identified 150 mCRPC patients with disease progression on
enzalutamide
or abiraterone. Of these 150 patients, 92 patients were chemo-naïve while 58 patients had previously received docetaxel chemotherapy before being started on second HT.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
When should ADT be started upon or after BCR in HSPC? An unanswered question.
Taken together with the results of the PROSPER trial (
enzalutamide
vs placebo) and the ARAMIS trial (darolutamide vs placebo), both of which also showed a survival advantage with the use of novel antiandrogen therapy in the nonmetastatic CRPC setting, there is now substantial evidence of significant
Taken together with the results of the PROSPER trial (
enzalutamide
vs placebo) and the ARAMIS trial (darolutamide vs placebo), both of which also showed a survival advantage with the use of novel antiandrogen therapy in the nonmetastatic CRPC setting, there is now substantial evidence of significant
MateoBeach
in
Advanced Prostate Cancer
4 years ago
23 months since chemo ended and still holding on Lupron/Enzalutamide
Adenocarcinoma is also responding to Lupron and
Enzalutamide
. (PSA <2). So my hybrid PC is now holding and I am enjoying whatever I can. This week we returned to a favorite spot to see the native Colorado columbine in bloom.
Adenocarcinoma is also responding to Lupron and
Enzalutamide
. (PSA <2). So my hybrid PC is now holding and I am enjoying whatever I can. This week we returned to a favorite spot to see the native Colorado columbine in bloom.
DenDoc
in
Advanced Prostate Cancer
4 years ago
BAT & Abiraterone / Enzalutamide resensitization
However, PSA50 responses to AR-targeted therapy rechallenge were higher in the post-
enzalutamide
cohort (68% vs 16%, p = 0.001).
However, PSA50 responses to AR-targeted therapy rechallenge were higher in the post-
enzalutamide
cohort (68% vs 16%, p = 0.001).
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Help with choosing treatment pathway
Oncologist #1 recommends combination treatment of ADT and AR agent (
Enzalutamide
) followed by chemo; whilst Oncologist #2 recommends combination of ADT and chemo followed by AR agent (
Enzalutamide
). Undecided on which recommendation to follow. Have PSMA PET-CT scheduled for 6th July.
Oncologist #1 recommends combination treatment of ADT and AR agent (
Enzalutamide
) followed by chemo; whilst Oncologist #2 recommends combination of ADT and chemo followed by AR agent (
Enzalutamide
). Undecided on which recommendation to follow. Have PSMA PET-CT scheduled for 6th July.
Ronnie7C
in
Advanced Prostate Cancer
4 years ago
PARP Inhibitors for Metastatic Castration-Resistant Prostate CancerInterview with Oliver Sartor MD
All the patients, in essence, were pretreated with abiraterone and
enzalutamide
, and they may or may not have been pretreated for docetaxel. The patients included not only BRCA1 and BRCA2, but in a “cohort A” also included patients with a deleterious mutation in ATM.
All the patients, in essence, were pretreated with abiraterone and
enzalutamide
, and they may or may not have been pretreated for docetaxel. The patients included not only BRCA1 and BRCA2, but in a “cohort A” also included patients with a deleterious mutation in ATM.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
Adverse events in the
enzalutamide
group were consistent with those previously reported for
enzalutamide
; the most frequently reported events were fatigue and musculoskeletal events.
Adverse events in the
enzalutamide
group were consistent with those previously reported for
enzalutamide
; the most frequently reported events were fatigue and musculoskeletal events.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Dr. Oliver Sartor on Rucaparib & Olaparib.
All the patients, in essence, were pretreated with abiraterone and
enzalutamide
, and they may or may not have been pretreated for docetaxel. The patients included not only BRCA1 and BRCA2, but in a “cohort A” also included patients with a deleterious mutation in ATM.
All the patients, in essence, were pretreated with abiraterone and
enzalutamide
, and they may or may not have been pretreated for docetaxel. The patients included not only BRCA1 and BRCA2, but in a “cohort A” also included patients with a deleterious mutation in ATM.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
To state the obvious: early use of Zytiga or Xtandi extends survival in APC
Here's what he replied: "Although long term androgen deprivation therapy may be
associated
with the development of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in a minority of patients, multiple studies have confirmed the long-term benefit of abiraterone and
enzalutamide
Here's what he replied: "Although long term androgen deprivation therapy may be
associated
with the development of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in a minority of patients, multiple studies have confirmed the long-term benefit of abiraterone and
enzalutamide
Tall_Allen
in
Advanced Prostate Cancer
4 years ago
Xtandi to Zytiga
I just finished 3 years of treatment with Xtandi (
enzalutamide
) with my psa going from 6.80 (07/19/17) and dropping to a low of 0.23 (03/15/18) . My psa then began a steady climb to 3.19 (08/02/19) and continued to 9.32 (07/16/20.
I just finished 3 years of treatment with Xtandi (
enzalutamide
) with my psa going from 6.80 (07/19/17) and dropping to a low of 0.23 (03/15/18) . My psa then began a steady climb to 3.19 (08/02/19) and continued to 9.32 (07/16/20.
docbulldog
in
Advanced Prostate Cancer
4 years ago
Comparing Benefit and Costs for Abiraterone and Enzalutamide in Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer
From the article: [i]"Ultimately, abiraterone and
enzalutamide
provide clinical benefit across all approved settings and have higher cost when used earlier in the course of metastatic prostate cancer.
From the article: [i]"Ultimately, abiraterone and
enzalutamide
provide clinical benefit across all approved settings and have higher cost when used earlier in the course of metastatic prostate cancer.
cujoe
in
Fight Prostate Cancer
4 years ago
Comparing the Clinical Efficacy and Safety of Abiraterone and Enzalutamide in Metastatic CRPC.
Keywords: Metastatic castration-resistant prostate cancer; abiraterone;
enzalutamide
; meta-analysis.
Keywords: Metastatic castration-resistant prostate cancer; abiraterone;
enzalutamide
; meta-analysis.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer in patients with PSADT <10 months.
"
Enzalutamide
was associated with a delay in the use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent antineoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig. S2A).
"
Enzalutamide
was associated with a delay in the use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent antineoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig. S2A).
tango65
in
Advanced Prostate Cancer
4 years ago
Final 5-yr Survival analysis in the PREVAIL trial.
Enzalutamide
reduced the hazard of death by 17% (hazard ratio 0.83 ..., despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and
enzalutamide
, respectively."
Enzalutamide
reduced the hazard of death by 17% (hazard ratio 0.83 ..., despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and
enzalutamide
, respectively."
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Clorgyline for Enzalutamide resistance.
New study below [1]. See also my prior post on Clorgyline [2]. "... most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection
New study below [1]. See also my prior post on Clorgyline [2]. "... most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Apalutamide and Overall Survival in Prostate Cancer
Taken together with the results of the PROSPER trial (
enzalutamide
vs placebo) and the ARAMIS trial (darolutamide vs placebo), both of which also showed a survival advantage with the use of novel antiandrogen therapy in the nonmetastatic CRPC setting, there is now substantial evidence of significant
Taken together with the results of the PROSPER trial (
enzalutamide
vs placebo) and the ARAMIS trial (darolutamide vs placebo), both of which also showed a survival advantage with the use of novel antiandrogen therapy in the nonmetastatic CRPC setting, there is now substantial evidence of significant
Balsam01
in
Advanced Prostate Cancer
4 years ago
1
...
24
25
26
...
42
Next page
10
20
30
40
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
760 results
Fight Prostate Cancer
56 results
Prostate Cancer Network
7 results
View top 10 communities
Sort by
Most Relevant
Newest